Skip to main content
reMYND reMYND reMYND
  • Home
  • Platform & products
      • Lead Alzheimer program ReS19-T
      • Lead Diabetes program ReS39
      • Epilepsy/Alzheimer’s program ReS3-T
      • Orphan programs
  • Services
      • APP-London model
      • APPxPS1 model
      • Tau[P301L] model
      • Tau[P301S] model
      • APP[V717I]xTau[P301L] model
      • APP[V717I]xTau[P301S] model
      • Seed and spread Tauopathy model
  • About us
      • People
      • News
          • reMYND extends Series B funding to EUR 24 million
          • reMYND commences first-in-human trial of ReS19-T Alzheimer’s program
          • reMYND appoints Dr. Lode Debrabandere as Chief Business Officer
          • reMYND announces Clinical Advisory Board to support development of Alzheimer’s programme
          • Interreg. project "Memories" update
          • Interreg. project "Memories" holds 2nd annual symposium & new newsletter is available
          • Approved project ‘Memories’ (‘Herinneringen’ in Dutch): early diagnostics of Alzheimer’s disease (AD)
      • Partners
  • Jobs
      • Business Development Director CRO
      • Office Assistant
  • Contact

Interreg Nederlands.pdf

  • Home
  • /
  • Interreg Nederlands.pdf
PDF icon Interreg Nederlands.pdf (357.07 KB)
  • Home
  • Platform & products
  • Services
  • About us
  • Jobs
  • Contact

Partners

Alt
Alt
Alt
Alt
Alt
Alt
Alt
Alt
vlaio
Flandersbio
Interreg Vlaanderen Nederland
Alt
Eureka

CRO News Flashes

Subscribe Inline

Contact

reMYND, Bio-Incubator (Wetenschapspark)
Gaston Geenslaan 1
BE-3001 Leuven (Heverlee)
Belgium

RPR Leuven, 0476.910.101
BTW/VAT: BE0476.910.101

T +32 16 75 14 20
F +32 16 75 14 21
info@remynd.com

Terms & conditions